320 related articles for article (PubMed ID: 24459652)
1. Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH) and LUTS/BPH with Erectile Dysfunction in Asian Men: A Systematic Review Focusing on Tadalafil.
Park HJ; Won JE; Sorsaburu S; Rivera PD; Lee SW
World J Mens Health; 2013 Dec; 31(3):193-207. PubMed ID: 24459652
[TBL] [Abstract][Full Text] [Related]
2. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
[TBL] [Abstract][Full Text] [Related]
4. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies.
Porst H; Roehrborn CG; Secrest RJ; Esler A; Viktrup L
J Sex Med; 2013 Aug; 10(8):2044-52. PubMed ID: 23782459
[TBL] [Abstract][Full Text] [Related]
5. Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia.
Govorov A; Kasyan G; Priymak D; Pushkar D; Sorsaburu S
Cent European J Urol; 2014; 67(2):167-77. PubMed ID: 25140232
[TBL] [Abstract][Full Text] [Related]
6. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
7. Erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) combined responders to tadalafil after 12 weeks of treatment.
Roehrborn CG; Egan KB; Miner MM; Ni X; Wong DG; Rosen RC
BJU Int; 2016 Jul; 118(1):153-60. PubMed ID: 26765325
[TBL] [Abstract][Full Text] [Related]
8. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
[TBL] [Abstract][Full Text] [Related]
9. A review of the use of tadalafil in the treatment of benign prostatic hyperplasia in men with and without erectile dysfunction.
Hatzimouratidis K
Ther Adv Urol; 2014 Aug; 6(4):135-47. PubMed ID: 25083163
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study.
Bechara A; Romano S; Casabé A; Haime S; Dedola P; Hernández C; Rey H
J Sex Med; 2008 Sep; 5(9):2170-8. PubMed ID: 18638006
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of tadalafil 5 mg once daily in the treatment of men with lower urinary tract symptoms suggestive to benign prostatic hyperplasia with or without erectile dysfunction: results from naturalistic observational TadaLutsEd study.
Bechara A; Casabe A; Rodriguez Baigorri G; Cobreros C
J Sex Med; 2014 Feb; 11(2):498-505. PubMed ID: 24224728
[TBL] [Abstract][Full Text] [Related]
12. Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.
Yokoyama O; Igawa Y; Takeda M; Yamaguchi T; Murakami M; Viktrup L
Ther Adv Urol; 2015 Oct; 7(5):249-64. PubMed ID: 26425140
[TBL] [Abstract][Full Text] [Related]
13. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.
Broderick GA; Brock GB; Roehrborn CG; Watts SD; Elion-Mboussa A; Viktrup L
Urology; 2010 Jun; 75(6):1452-8. PubMed ID: 20163842
[TBL] [Abstract][Full Text] [Related]
14. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
Amano T; Earle C; Imao T; Matsumoto Y; Kishikage T
Aging Male; 2018 Mar; 21(1):77-82. PubMed ID: 28830281
[TBL] [Abstract][Full Text] [Related]
15. Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Gonzalez RR; Kaplan SA
Expert Opin Drug Metab Toxicol; 2006 Aug; 2(4):609-17. PubMed ID: 16859408
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil for the treatment of benign prostatic hyperplasia.
Mónica FZ; De Nucci G
Expert Opin Pharmacother; 2019 Jun; 20(8):929-937. PubMed ID: 30901259
[TBL] [Abstract][Full Text] [Related]
17. [Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia].
Yuan RQ
Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1147-51. PubMed ID: 23405801
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.
Egerdie RB; Auerbach S; Roehrborn CG; Costa P; Garza MS; Esler AL; Wong DG; Secrest RJ
J Sex Med; 2012 Jan; 9(1):271-81. PubMed ID: 21981682
[TBL] [Abstract][Full Text] [Related]
19. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
[TBL] [Abstract][Full Text] [Related]
20. Treatment satisfaction among men with concurrent benign prostatic hyperplasia and erectile dysfunction treated with tadalafil or other phosphodiesterase type-5 inhibitor combinations.
Lee LK; Goren A; Boytsov NN; Donatucci CF; McVary KT
Patient Prefer Adherence; 2016; 10():1205-15. PubMed ID: 27471377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
